Tier 2 — strong

Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial

Qian Qi, Yirepanjaing Ailiyaer, Ruijuan Liu, Yan Zhang, Caiyu Li, Mingtao Liu, Xiuxiu Wang, Lijun Jing, Yu Li
Respir Res 2019 20(1):73

Bibliography

PubMed
PMID 30975143
PubMed Central
PMC6458826
DOI
10.1186/s12931-019-1042-x
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignRandomized controlled trial
ModelHuman
Sample161 adults with bronchiectasis
InterventionNAC 600 mg twice daily versus control
Duration12 months
EndpointsExacerbations; Sputum volume; Quality of life

What the study showed, in plain terms

Long-term bronchiectasis trial testing oral NAC as a mucolytic/antioxidant strategy.

Key findings

NAC was associated with fewer exacerbations, lower sputum volume and improved quality-of-life measures.

What this study can and cannot tell us

Open-label elements/control structure can increase bias; single disease context.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology